JPRN-UMIN000048724已完成2 期
A multicenter, phase II study of full-dose THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, aggressive non-Hodgkin lymphoma - THP-1
the Hematological Malignancy Clinical Study Group0 个研究点目标入组 30 人开始时间: 2022年8月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
The CR rate was 65.5% (95% confidence interval, 45.7~82.1%). The 3-year failure-free and overall survival rates were 54.1% and 53.9%, respectively.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 70years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •any other malignancies, mental illness, myocardial infarction or angina history, central nervous system infiltration, uncontrollable diabetes, human immunodeficiency virus infection, hepatitis B virus surface antigen, and/or hepatitis C virus antibody positivity were excluded.
研究者
相似试验
已完成
2 期
Phase II study of R-CHOP and R-high-dose MTX therapy for IVLBCL (PRIMEUR-IVL)Intravascular large B-cell lymphomaJPRN-UMIN000005707IVL study group in Japan38
已完成
2 期
Phase 2 study evaluating the efficacy and safety of the combination of Bendamustine, Rituximab and Dexamethazone (RBenda-D) for treatment of CD20-positive relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.Relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.JPRN-UMIN000008145Kyoto Prefectural University of Medicine/K-LSG33
已完成
3 期
Adjuvant Chemotherapy for colon cancer with HIgh EVidencE(JFMC47-1202-C3: ACHIEVE Trial)stage III colon cancer (including rectosigmoid cancer)JPRN-jRCTs031180129Yoshino Takayuki1,291
已完成
2 期
A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant PatientsKidney TransplantationNCT00106639Pfizer61
已完成
不适用
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for cisplatin containing regimemalignant tumor(only solid tumor)JPRN-UMIN000036489niversity of Shizuoka, School of Pharmaceutical Sciences85